 |
|
Treatment-induced growth factor causes cancer progression
April 06, 2007In advanced cancer, anti-tumor therapies often work only partially or not at all, and tumors progress following treatment.
Vanderbilt-Ingram Cancer Center scientists have now linked a treatment-induced growth factor to the cancer's future spread.
The team led by Carlos Arteaga, M.D., reports in the May issue of the Journal of Clinical Investigation that radiation and chemotherapy increase circulating levels of the growth factor TGF-beta, circulating cancer cells, and tumor metastases in a mouse model of metastatic breast cancer.
Blocking TGF-beta in the model prevented tumor metastases, suggesting that TGF-beta inhibitors may be clinically useful in combination with primary therapies.
Arteaga and colleagues had previously shown that a brief induction of TGF-beta in a transgenic mouse model of breast cancer dramatically accelerated metastasis.
Then they came across a few clinical studies showing that radiation and chemotherapy increase TGF-beta in patients or in experimental tumors.
"We wondered then if TGF-beta induced by anti-cancer therapies can serve as a survival signal for tumor cells, thus allowing them to withstand therapy and later recur," said Arteaga, professor of Medicine and Cancer Biology and director of the Vanderbilt-Ingram Breast Cancer Program.
This appears to be the case, he said. Radiation therapy and the chemotherapeutic agents doxorubicin and docetaxel all increased TGF-beta levels and accelerated metastasis, an effect that was blocked by neutralizing antibodies directed against TGF-beta.
Similar results not reported in this paper have been observed with small molecule inhibitors of the TGF-beta type I receptor kinase.
"We speculate, based on these observations, that this will occur in some patients," Arteaga said.
Patients who have treatment-induced increases in TGF-beta may not respond as well to the anti-cancer therapy as those who do not, and this is a testable hypothesis, he added.
The team is currently assessing TGF-beta levels in the serum of patients with breast cancer who are being treated with neoadjuvant chemotherapy to shrink the tumor prior to surgery.
"We'll be looking to see in what proportion of patients the serum and tumor TGF-beta goes up, and whether the increase correlates with the inability of the therapy to eliminate the cancer in the breast," Arteaga said.
Increased circulating and/or tumor TGF-beta in response to treatment may be a marker of tumors destined to progress rapidly after therapy, he said. Patients with such tumors might benefit from the addition of TGF-beta inhibitors to the primary therapy. Several TGF-beta inhibitors are currently in early stage clinical trials, some of which are being conducted at Vanderbilt.
"It probably isn't just TGF-beta that is having this effect," Arteaga said. "There are other growth factors and cytokines that have been reported to increase in response to radiation, chemotherapy and surgery, and some of these could also be tumor survival and prometastatic signals. "TGF-beta may be just the tip of the iceberg.\\\
Vanderbilt University Medical Center
Blocking TGF-beta in the model prevented tumor metastases, suggesting that TGF-beta inhibitors may be clinically useful in combination with primary therapies.
Arteaga and colleagues had previously shown that a brief induction of TGF-beta in a transgenic mouse model of breast cancer dramatically accelerated metastasis.
Then they came across a few clinical studies showing that radiation and chemotherapy increase TGF-beta in patients or in experimental tumors.
"We wondered then if TGF-beta induced by anti-cancer therapies can serve as a survival signal for tumor cells, thus allowing them to withstand therapy and later recur," said Arteaga, professor of Medicine and Cancer Biology and director of the Vanderbilt-Ingram Breast Cancer Program.
This appears to be the case, he said. Radiation therapy and the chemotherapeutic agents doxorubicin and docetaxel all increased TGF-beta levels and accelerated metastasis, an effect that was blocked by neutralizing antibodies directed against TGF-beta.
Similar results not reported in this paper have been observed with small molecule inhibitors of the TGF-beta type I receptor kinase.
"We speculate, based on these observations, that this will occur in some patients," Arteaga said.
Patients who have treatment-induced increases in TGF-beta may not respond as well to the anti-cancer therapy as those who do not, and this is a testable hypothesis, he added.
The team is currently assessing TGF-beta levels in the serum of patients with breast cancer who are being treated with neoadjuvant chemotherapy to shrink the tumor prior to surgery.
"We'll be looking to see in what proportion of patients the serum and tumor TGF-beta goes up, and whether the increase correlates with the inability of the therapy to eliminate the cancer in the breast," Arteaga said.
Increased circulating and/or tumor TGF-beta in response to treatment may be a marker of tumors destined to progress rapidly after therapy, he said. Patients with such tumors might benefit from the addition of TGF-beta inhibitors to the primary therapy. Several TGF-beta inhibitors are currently in early stage clinical trials, some of which are being conducted at Vanderbilt.
"It probably isn't just TGF-beta that is having this effect," Arteaga said. "There are other growth factors and cytokines that have been reported to increase in response to radiation, chemotherapy and surgery, and some of these could also be tumor survival and prometastatic signals. "TGF-beta may be just the tip of the iceberg.\\\
Vanderbilt University Medical Center
Cancer Progression Current Events and Cancer Progression News RSSNew Notre Dame study provides insights into the molecular basis of tumor cell behavior
A new study by a team of researchers led by Crislyn D'Souza-Schorey, associate professor of biological sciences at the University of Notre Dame, sheds light on the molecular basis by which tumor cells modulate their surroundings to favor cancer progression.
Time in a bottle: Scientists watch evolution unfold
A 21-year Michigan State University experiment that distills the essence of evolution in laboratory flasks not only demonstrates natural selection at work, but could lead to biotechnology and medical research advances, researchers said.
Depression increases cancer patients' risk of dying
Depression can affect a cancer patient's likelihood of survival. That is the finding of an analysis published in the November 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society.
Researchers uncover potential mechanisms to protect against genetic alterations, diseases
Peering into the DNA of tiny yeast, researchers at the Moores Cancer Center at the University of California, San Diego and the San Diego Branch of the Ludwig Institute for Cancer Research have pinpointed a large number of genes that can prevent a type of genetic rearrangement that may lead to cancer and other diseases.
New Tool May Help with Early Detection of Deadly Pancreatic Cancer
A new diagnostic tool developed by Van Andel Research Institute (VARI) scientists has shown promising results when used with patients of pancreatic cancer, one of the deadliest forms of cancer due to the difficulty of diagnosing it in its early stages.
1 gene that contributes to breast cancer's aggressive behavior identified
Aggressive forms of cancer are often driven by the abnormal over-expression of cancer-promoting genes, also known as oncogenes.
Green tea may affect prostate cancer progression
According to results of a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research, men with prostate cancer who consumed the active compounds in green tea demonstrated a significant reduction in serum markers predictive of prostate cancer progression.
Prostate cancer test improves prediction of disease course
A new prostate cancer risk assessment test, developed by a UCSF team, gives patients and their doctors a better way of gauging long-term risks and pinpointing high risk cases.
Protein linked to change in tissue that surround and support breast tumors
A protein known to be overly active in breast cancer can exist in a form that seems to change the structural composition of mammary tissue, potentially making it more conducive to tumor progression, say researchers from the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC).
Vaporized viral vector shows promise in anti-cancer gene therapy
A new lung cancer therapy employing a vaporized viral vector to deliver a cancer-inhibiting molecule directly to lung tissue shows early promise in mouse trials, according to researchers at the Ministry of Education, Science and Technology in Korea.
More Cancer Progression Current Events and Cancer Progression News Articles
 |
Modeling Cancer Progression on the Pathway Level: Assessing Cancer Progression via Pathway Dependencies by Elena Edelman (Author) Over the past several decades, many genes have been discovered that govern important function in the development of a variety of different cancers. However, biological insight from the list of genes is still limited and the underlying mechanisms that occur in the cell during tumorigenesis have not been well established. Studying cancer progression in terms of the oncogenic pathways that are responsible for specific actions that change normal cells into tumors is a means for bringing insight onto these issues. The work presented here will uncover mechanisms that are occurring at the pathway level that first initiate tumor formation and then continue through cancer progression and finally metastasis. Using gene expression datasets we utilized novel statistical methods to uncover ... |
 |
Selected Aspects of Cancer Progression: Metastasis, Apoptosis and Immune Response (Cancer Growth and Progression) by Hans E. Kaiser (Author), Hans E. Kaiser (Editor), Aejaz Nasir (Editor) The processes of tumor metastasis, apoptosis and anti-tumor immune response are among the most complex yet rapidly advancing fields in the area of cancer research. This monogaph presents a comprehensive coverage of the recent advances in the various key concepts in these fundamental aspects of human cancer. It would be of particular interest to members of the cancer research community, especially those who are actively involved in the study of basic and translational aspects of human cancer. Specifically, this volume includes authentic subject reviews by leading experts on the following aspects: Control of tumor cell motility Role of tumor-cell adhesion and migration in organ-selective metastasis-formation Tumor heterogeneity in relation to invasion and metastasis and its... |
 |
Bone Cancer: Progression and Therapeutic Approaches by Dominique Heymann (Editor) The epidemiological and clinical importance of bone metastasis has long been recognized, but the past decade has seen an explosion in the fields of bone biology and bone cancer research. This period of time has been marked by a number of key discoveries that have led to the opening up of entirely new areas for investigation as well as new therapies which combine surgery and biological therapeutic approaches. Bone is a common site of cancer metastases - cancer cells commonly develop in bone and spread to other organ systems through the bloodstream. For example, the incidence of bone metastases in breast and prostate cancers is 70%, whereas it is only 30 to 40% in metastatic lung cancer. In clinical terms, bone metastases have substantial negative effects on a patient's quality of... |
|
Behavior and Cancer: Life-Style and Psychosocial Factors in the Initiation and Progression of Cancer (Jossey Bass Social & Behavioral Science Series) by Sandra M. Levy (Author) | |
 |
HMGA1 and Cancer Progression by Nathan Treff (Author) High Mobility Group (HMG) A1 proteins are gene regulatory factors whose overexpression is frequently observed in naturally occurring human cancers. Overexpression of transgenic HMGA1 proteins in cells results in neoplastic transformation and promotes progression to malignant cellular phenotypes. The following thesis describes evidence indicating that two likely mechanisms in which the HMGA1a protein promotes malignant changes in cells are through increased sensitivity to activation of the Ras/ERK signaling pathway and by direct regulation of KIT ligand gene expression. These results implicate both HMGA1 as a chemotherapeutic target for Ras/ERK signaling inhibition and plasma KIT ligand as a diagnostic marker for HMGA1-positive carcinomas. In addition, the following... |
|
SATRAPLATIN REDUCES RISK OF PROSTATE CANCER PROGRESSION.: An article from: Worldwide Biotech by Gale Reference Team (Author) This digital document is an article from Worldwide Biotech, published by Thomson Gale on April 1, 2007. The length of the article is 1643 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: SATRAPLATIN REDUCES RISK OF PROSTATE CANCER PROGRESSION. Author: Gale Reference Team Publication: Worldwide Biotech (Newsletter) Date: April 1, 2007 Publisher: Thomson Gale Volume: 19 Issue: 4 Page: NA Distributed by Thomson... | |
 |
Immunological Aspects of Neoplasia - The Role of the Thymus (Cancer Growth and Progression) by Bela Bodey (Author), Stuart E. Siegel (Author), Hans E. Kaiser (Author) Our work began where the greatest classical morphologists left off; their best work was the start of ours. As our work progressed, the rigidity of basic, previous embryological principles was broken down as scientific knowledge advanced. At the same time, the molecular, biological characterization of the cell surface receptor systems progressed enormously with the invention of NUMEROUS monoclonal antibodies. Thus, thymology became once again very important because the thymus is the first and central organ of the human immunological system. Then, the question of immuno-neuroendocrine regulation arose and has only been partially answered. Our book seeks to explore what has not been explored. The topic of thymic epithelial cells is a unique one and has never been explored in any previous... |
|
Local Invasion and Spread of Cancer (Cancer Growth and Progression) by Kenneth W. Brunson (Editor) | |
|
DNA Abnormalities Predict Progression to Oral Cancer.(oral leukoplakia progression to squamous cell carcinoma): An article from: Skin & Allergy News by Robert Finn (Author) This digital document is an article from Skin & Allergy News, published by International Medical News Group on October 1, 2001. The length of the article is 988 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: DNA Abnormalities Predict Progression to Oral Cancer.(oral leukoplakia progression to squamous cell carcinoma) Author: Robert Finn Publication: Skin & Allergy News (Magazine/Journal) Date: October 1, 2001 Publisher: International Medical News Group Volume: 32 Issue: 10 Page: 33 Distributed by Thomson... | |
|
Etiology of Cancer in Man (Cancer Growth and Progression) by Arthur S. Levine (Editor) |
| © 2009 BrightSurf.com |